Evaluation of the Pharmacokinetics and Safety of VX-548 in Participants With Mild or Moderate Hepatic Impairment

Completed · Phase 1

Conditions studied: Pain

In brief

The purpose of this study is to evaluate the pharmacokinetics and safety of multiple doses of VX-584 in participants with mild or moderate hepatic impairment as compared to matched healthy controls.

Key facts

Study ID

NCT05560464

Run by

Vertex Pharmaceuticals Incorporated

People needed

36

Starts

2022-10-14

Expected to finish

2023-07-24

Last updated by the study team

2024-03-20

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Where it is running

• Division of Clinical Pharmacology, University of Miami — Miami, Florida, United States
• Orlando Clinical Research Center — Orlando, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.